title: Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Motzer
authors.forename: T
authors.initials: T
authors.lastname: Johnson
authors.forename: T K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: K C
authors.initials: KC
authors.lastname: Deen
authors.forename: Z
authors.initials: Z
authors.lastname: Xue
authors.forename: L N
authors.initials: LN
authors.lastname: Pandite
authors.forename: C
authors.initials: C
authors.lastname: Carpenter
authors.forename: C F
authors.initials: CF
authors.lastname: Xu
mesh_terms: D001663:Bilirubin / Q000302:isolation & purification / Q000378:metabolism; D054316:Biomarkers, Pharmacological; D056726:Genetic Association Studies; D005838:Genotype; D005878:Gilbert Disease / Q000139:chemically induced / Q000235:genetics / Q000473:pathology; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D006932:Hyperbilirubinemia / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D007191:Indazoles; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008099:Liver / Q000187:drug effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D000077210:Sunitinib; D000099148:UGT1A1 Enzyme
chemical_list: D001663:Bilirubin; D054316:Biomarkers, Pharmacological; D014453:Glucuronosyltransferase; D007191:Indazoles; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000077210:Sunitinib; D000099148:UGT1A1 Enzyme; C516667:pazopanib